Jacobs Levy Equity Management Inc. acquired a new stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 143,679 shares of the company's stock, valued at approximately $736,000. Jacobs Levy Equity Management Inc. owned 0.10% of Adaptive Biotechnologies as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of ADPT. JTC Employer Solutions Trustee Ltd purchased a new stake in shares of Adaptive Biotechnologies during the third quarter valued at $26,000. Ashton Thomas Securities LLC purchased a new stake in shares of Adaptive Biotechnologies during the third quarter valued at $34,000. Rothschild Investment LLC purchased a new stake in shares of Adaptive Biotechnologies during the second quarter valued at $36,000. MQS Management LLC purchased a new stake in shares of Adaptive Biotechnologies during the second quarter valued at $36,000. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Adaptive Biotechnologies by 769.6% during the second quarter. Nisa Investment Advisors LLC now owns 13,392 shares of the company's stock valued at $48,000 after purchasing an additional 11,852 shares during the last quarter. Institutional investors and hedge funds own 99.17% of the company's stock.
Analyst Ratings Changes
ADPT has been the subject of several analyst reports. Piper Sandler upped their target price on Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an "overweight" rating in a report on Monday, November 11th. BTIG Research upped their price target on Adaptive Biotechnologies from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Wednesday, October 2nd.
Get Our Latest Analysis on Adaptive Biotechnologies
Adaptive Biotechnologies Stock Performance
NASDAQ:ADPT traded up $0.27 during trading hours on Tuesday, hitting $6.71. 1,440,073 shares of the company's stock traded hands, compared to its average volume of 1,415,311. The firm has a market cap of $990.26 million, a P/E ratio of -5.01 and a beta of 1.49. Adaptive Biotechnologies Co. has a twelve month low of $2.28 and a twelve month high of $7.07. The stock's fifty day moving average price is $5.31 and its two-hundred day moving average price is $4.53.
Adaptive Biotechnologies Company Profile
(
Free Report)
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Recommended Stories
Before you consider Adaptive Biotechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptive Biotechnologies wasn't on the list.
While Adaptive Biotechnologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
